Dr. Anil Patri serves as the Chair, Nanotechnology Task Force and Director of Nanocore, National Center for Toxicological Research, US Food and Drug Administration. His laboratory is very active in regulatory science research to understand material characteristics, safety and efficacy of products containing nanomaterial, and provides training to scientists and reviewers at FDA. He serves on the U.S. National Nanotechnology Initiative (NNI) NSET Subcommittee and NEHI working group for inter-agency coordination. He is as member of ISO TC229 and serves on the executive committee of ASTM E56 to facilitate standards development in Nanotechnology. He co-chairs the EU-US Nanomedicine and Characterization Communities of Research.